Stockreport
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant that eliminates the need for insulin or immunosuppressive drugs[1]. Meanwhile, stem cell therapies are restoring natural insulin production in human trials, with some patients achieving insulin independence for over a year[2]. As the healthcare industry pivots from managing symptoms to engineering biological solutions, five companies are positioning themselves at the forefront of this regenerative revolution: Avant Technologies, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Novo Nordisk (NYSE: NVO), CRISPR Therapeutics (NASDAQ: CRSP), and Sernova Biotherapeutics (TSX: SVA) (OTCPK: SEOVF). Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems tran
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | VRTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
VRTX alerts
VRTX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
NEWS
NEWS
- How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review [Yahoo! Finance][Yahoo! Finance]
- Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025? [Yahoo! Finance][Yahoo! Finance]
- Sharp Rise in Senior Overdose Deaths Drives Launch of New Healthy Aging Video Program [Yahoo! Finance][Yahoo! Finance]
- Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by analysts at Wells Fargo & Company from $460.00 to $515.00. They now have an "overweight" rating on the stock.[MarketBeat]
- Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.[MarketBeat]
- More
VRTX
SEC Filings
SEC Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- VRTX's page on the SEC website
- More